17 Patents
- US121802592024Peptides and Combination of Peptides for Use in Immunotherapy Against Prostate Cancer and Other Cancers
Immatics Biotechnologies GmbH
0 cites - US121448522024Peptides and Combination of Peptides for Use in Immunotherapy Against Prostate Cancer and Other Cancers
Immatics Biotechnologies GmbH
0 cites - US121215722024Peptides and Combination of Peptides for Use in Immunotherapy Against Hepatocellular Carcinoma (HCC) and Other Cancers
Immatics Biotechnologies GmbH
0 cites - US121026702024Peptides and Combination of Peptides for Use in Immunotherapy Against Prostate Cancer and Other Cancers
Immatics Biotechnologies GmbH
0 cites - US120972482024Peptides and Combination of Peptides for Use in Immunotherapy Against Hepatocellular Carcinoma (HCC) and Other Cancers
IMMATICS BIOTECHNOLOGIES GmbH
0 cites - US120972492024Peptides and Combination of Peptides for Use in Immunotherapy Against Prostate Cancer and Other Cancers
Immatics Biotechnologies GmbH
0 cites - US120763802024Peptides and Combination of Peptides for Use in Immunotherapy Against Hepatocellular Carcinoma (HCC) and Other Cancers
Immatics Biotechnologies GmbH
0 cites - US120763812024Peptides and Combination of Peptides for Use in Immunotherapy Against Prostate Cancer and Other Cancers
Immatics Biotechnologies GmbH
0 cites - US120704912024Peptides and Combination of Peptides for Use in Immunotherapy Against Hepatocellular Carcinoma (HCC) and Other Cancers
Immatics Biotechnologies GmbH
0 cites - US118264092023Peptides and Combination of Peptides for Use in Immunotherapy Against Prostate Cancer and Other Cancers
IMMATICS BIOTECHNOLOGIES GmbH
0 cites - US117865832023Peptides and Combination of Peptides for Use in Immunotherapy Against Hepatocellular Carcinoma (HCC) and Other Cancers
IMMATICS BIOTECHNOLOGIES GmbH
0 cites - US117865842023Peptides and Combination of Peptides for Use in Immunotherapy Against Prostate Cancer and Other Cancers
Immatics Biotechnologies GmbH
0 cites - US117796382023Method of Eliciting a CD8+ Cytotoxic Response in Hepatocellular Carcinoma Patients with a Population of Activated T Cells
IMMATICS BIOTECHNOLOGIES GmbH
0 cites - US116791472023Method of Eliciting a CD8+ Cytotoxic Response in Hepatocellular Carcinoma Patients with a Population of Activated T Cells
IMMATICS BIOTECHNOLOGIES GmbH
0 cites - US116728482023Method of Eliciting a CD8+ Cytotoxic Response in Hepatocellular Carcinoma Patients with a Population of Activated T Cells
IMMATICS BIOTECHNOLOGIES GmbH
0 cites - US115769562023Peptides and Combination of Peptides for Use in Immunotherapy Against Hepatocellular Carcinoma (HCC) and Other Cancers
IMMATICS BIOTECHNOLOGIES GmbH
0 cites - US115595732023Method of Eliciting a CD8+ Cytotoxic Response in Hepatocellular Carcinoma Patients with a Population of Activated T Cells
IMMATICS BIOTECHNOLOGIES GmbH
0 cites